Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Smith & Nephew SNATS, Inc. Common Stock (NY:SNN)

30.25 +1.52 (+5.29%)
Official Closing Price Updated: 4:10 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,705,744
Open 29.57
Bid (Size) 29.66 (100)
Ask (Size) 34.80 (100)
Prev. Close 28.73
Today's Range 29.53 - 30.30
52wk Range 28.55 - 38.79
Shares Outstanding N/A
Dividend Yield 3.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Smith & Nephew plc (NYSE:SNN) Caviar Cruise Screen Analysis ↗
Via Chartmill
News headline image
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Issued on behalf of Conexeu Sciences Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
-8.0%
-8.0%
1 Month
+2.6%
+2.6%
3 Month
-5.7%
-5.7%
6 Month
-7.8%
-7.8%
1 Year
-1.1%
-1.1%

More News

Read More
News headline image
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
From Smith & Nephew UK Ltd
Via GlobeNewswire
Smith & Nephew (NYSE:SNN) Qualifies as a Quality Investment Through the Caviar Cruise Screen ↗
Via Chartmill
Smith & Nephew PLC (NYSE:SNN) Passes the Caviar Cruise Screen for Quality Investing ↗
Via Chartmill
News headline image
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
From World Street Intelligence
Via GlobeNewswire
News headline image
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
New data for Smith+Nephew’s CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew signs distribution agreement with SI-BONE
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith & Nephew PLC (NYSE:SNN): A Value Investment in Medical Devices ↗
Via Chartmill
News headline image
Smith+Nephew comparative study1 shows  PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
UFC® and Smith+Nephew announce multi-year extension of partnership
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Organogenesis Holdings (ORGO) Battles Headwinds: Can This Regenerative Medicine Innovator Stage a Comeback?
Via MarketMinute
Topics Fraud
News headline image
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty
From Smith & Nephew UK Ltd
Via GlobeNewswire
News headline image
Trump Administration Review Targets Medical Supply Chain Vulnerabilities ↗
Via Benzinga
Topics Economy Government Supply Chain
News headline image
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
From Smith & Nephew UK Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Smith & Nephew SNATS, Inc. Common Stock publicly traded?
Yes, Smith & Nephew SNATS, Inc. Common Stock is publicly traded.
What exchange does Smith & Nephew SNATS, Inc. Common Stock trade on?
Smith & Nephew SNATS, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Smith & Nephew SNATS, Inc. Common Stock?
The ticker symbol for Smith & Nephew SNATS, Inc. Common Stock is SNN on the New York Stock Exchange
What is the current price of Smith & Nephew SNATS, Inc. Common Stock?
The current price of Smith & Nephew SNATS, Inc. Common Stock is 30.25
When was Smith & Nephew SNATS, Inc. Common Stock last traded?
The last trade of Smith & Nephew SNATS, Inc. Common Stock was at 07/02/26 04:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.